Renal Cancer - Results from #1080

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. February 14, 2023

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities. February 13, 2023

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. February 13, 2023

Oncologic and perioperative outcomes of laparoscopic versus open radical nephrectomy for the treatment of renal tumor (> 7 cm): a systematic review and pooled analysis of comparative outcomes. February 10, 2023

LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. February 10, 2023

A Matched Analysis of Active Surveillance Versus Nephrectomy for T1a Small Renal Masses. February 9, 2023

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. February 9, 2023

Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell Carcinoma. February 8, 2023

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma. February 8, 2023

Stereotactic body radiation therapy for kidney cancer. Where do we stand? February 8, 2023

Comparative diagnostic performance of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for differentiating clear cell and non-clear cell renal cell carcinoma. February 7, 2023

Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. February 7, 2023

Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm. February 6, 2023

Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. February 6, 2023

The prognostic value and immune correlation of IL18 expression and promoter methylation in renal cell carcinoma. February 3, 2023

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments. February 3, 2023

The IRON Study: Investigation of Robot-assisted Versus Open Nephron-sparing Surger February 2, 2023

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. February 2, 2023

ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway. February 2, 2023

The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. February 1, 2023

Page 55 of 456